Tags: Drug.

Dolutegravir (DTG) is an FDA-approved drug for the treatment of HIV infection. Dolutegravir is an integrase inhibitor. Known as S/GSK1349572 or just 572 the drug is marketed as Tivicay by GlaxoSmithKline (GSK). In February 2013 the Food and Drug Administration announced that it would fast track dolutegravir’s approval process.On August 13 2013 dolutegravir was approved by the FDA. On November 4 2013 dolutegravir was approved by Health Canada.

Dolutegravir.svg
ATC prefix
J05
ATC suffix
AX12
CAS number
1051375-16-6
FDA UNII code
DKO1W9H7M1
IUPAC name
(4R12aS)-N-(24-difluorobenzyl)-7-hydroxy-4-methyl-68-dioxo-34681212a-hexahydro-2H-pyrido[1'2':45]pyrazino[21-b][13]oxazine-9-carboxamide
PubChem
54726191

Loading...

This page contains content from the copyrighted Wikipedia article "Dolutegravir"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.